AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00002961 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) >/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses >3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-
Study NCT02950844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel mapping algorithm
Description: Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF.
Study NCT02576808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger extract
Description: Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
Study NCT02576808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
Study NCT04046250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK-112690
Description: TK112690 treatment pre-methotrexate treatment
Study NCT04046250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TK-112690
Description: Placebo
Study NCT03834220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1347
Description: Debio 1347 oral tablets.
Study NCT01031862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3H-Cholesterol
Description: A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
Study NCT01140646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine disulfate p-toluene-sulfonate
Description: Given orally
Study NCT01140646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03395002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder
Description: Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.
Study NCT03395002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg Inhalation Powder
Description: Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.
Study NCT03395002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder
Description: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
Study NCT03887858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tab.
Description: Harnal-D Tab. 1T single oral administration under fasting
Study NCT03887858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tamsulosin HCl Tab.
Description: Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
Study NCT01553643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb Huang-Chi-Wu-Wu-Tang
Description: Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
Study NCT01553643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: at a rate of 3g two times per day
Study NCT01735370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Tablets USP 500mg
Description: 500 mg tablet once a day
Study NCT01735370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Tablets USP 500 mg
Description: 500 mg tablet once a day
Study NCT01264419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk Road Embolic Protection System
Description: System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
Study NCT00888485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral interventional program
Description: Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
Study NCT00888485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral interventional program
Description: Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
Study NCT02478255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 129-Xenon gas
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
Study NCT02478255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
Study NCT00208351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultima LX Collared Stem - Non-Polished/Blasted Finished
Description: A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
Study NCT00208351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultima LX Collared Stem - Polished Finished
Description: A collared polished finished cementless femoral component for use in total hip replacement.
Study NCT00208351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultima LX Collarless Stem - Non-Polished/Blasted Finished
Description: A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
Study NCT00208351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultima LX Collarless Stem - Polished finished
Description: A collarless polished finished cementless femoral component for use in total hip replacement.
Study NCT02561559 — intervention group
Intervention type: RADIATION
Intervention: Lung metastasis from soft-tissue sarcoma
Description: Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
Study NCT03753139 — intervention group
Intervention type: DEVICE
Intervention: Heart rhythm monitoring with portable device
Description: The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel.
Study NCT01140646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT04160494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT (6920 ng/mL via convection-enhanced delivery)
Description: dual-specific mAB
Study NCT03975569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic vaginal gel
Description: Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10\^9-10\^10 colony forming units of lactobacilli.
Study NCT01942070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Study NCT01942070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durable polymer everolimus-eluting metallic stent
Study NCT01392287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8
Study NCT00613093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temodar and O6-Benzylguanine (BG)
Description: Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle.
Study NCT00852241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restalyne
Description: one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
Study NCT02708147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotheraphy + Conventional treatment
Description: The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
Study NCT02708147 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
Study NCT00852241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perlane
Description: One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
Study NCT03369236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danicopan
Description: Danicopan was administered as an oral tablet.
Study NCT03369236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danicopan
Description: Danicopan was administered as an oral tablet.
Study NCT03369236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo was administered as an oral tablet.
Study NCT05982002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy-restricted diet
Description: energy intake was 500K calorie below daily requirements on average three meals at the same time of the day
Study NCT05982002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet
Description: energy intake was 500K calorie below daily requirements on average three meals at the same time of the day
Study NCT02698111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: donafenib 200mg，bid
Study NCT01820455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine, Mupirocin
Description: Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
Study NCT01820455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soap baths, Lubricating Jelly
Description: Soap and water baths with lubricating jelly to the nares, once daily for 5 days
Study NCT04160494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every three weeks)
Description: programmed cell death ligand 1 (PD-L1) blocking antibody
Study NCT05017961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft
Description: An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.
Study NCT05017961 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Allograft only
Description: The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.
Study NCT05017961 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Allograft combined with BMAC
Description: A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
Study NCT01119781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017(peginterferon beta-1a)
Description: peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
Study NCT03806608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crestal
Description: Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
Study NCT03806608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcrestal
Description: Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
Study NCT02619643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)
Study NCT02619643 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (Magstim)
Study NCT02312258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ixazomib placebo-matching capsules.
Study NCT02312258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study NCT03147222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fracture Care at Home
Description: This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
Study NCT03730727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
Study NCT03730727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
Study NCT03730727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
Study NCT03730727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal
Description: Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
Study NCT03672253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T Re-treatment
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
Study NCT02049970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
Study NCT04160494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
Description: dual-specific mAB
Study NCT04426227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze training
Description: A training module in gaze training for peripheral nerve blockade
Study NCT02049970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 30 ml 0.25 % bupivacaine is applied around brachial plexus
Study NCT02587091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portable obstetric ultrasound
Description: This intervention was advertised at the cluster level
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
Study NCT04340076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.